Table 2.
Characteristics of general users prescribed sodium hyaluronate eye drops over time.
| 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General users | 24,805 | 33,626 | 46,440 | 58,287 | 68,991 | 80,978 | 88,583 | 99,709 | 111,844 | 116,520 | 122,295 | 126,647 | 132,566 | 137,050 |
| Prevalence (100,000 person) | 2,562 | 3,435 | 4,695 | 5,829 | 6,899 | 8,098 | 8,914 | 10,092 | 11,386 | 11,935 | 12,602 | 13,130 | 13,823 | 14,372 |
| Sex | ||||||||||||||
| Female (%) | 17,066 (69%) | 22,765 (68%) | 31,301 (67%) | 38,644 (66%) | 45,534 (66%) | 53,445 (66%) | 58,288 (66%) | 65,210 (65%) | 73,146 (65%) | 76,903 (66%) | 80,226 (66%) | 83,334 (66%) | 87,228 (66%) | 90,042 (66%) |
| Age | ||||||||||||||
| Mean (SD) | 42.1 (17.7) | 43.6 (18.0) | 44.7 (18.1) | 45.7 (18.5) | 46.9 (19.0) | 47.5 (19.3) | 48.8 (19.3) | 49.3 (19.4) | 49.3 (19.7) | 50.0 (19.6) | 50.2 (19.7) | 50.8 (19.7) | 51.5 (19.6) | 51.9 (19.5) |
| Region | ||||||||||||||
| Seoul | 5,561 (22%) | 7,511 (22%) | 10,321 (22%) | 12,578 (22%) | 14,533 (21%) | 16,616 (21%) | 18,038 (20%) | 20,138 (20%) | 22,671 (20%) | 23,197 (20%) | 23,843 (19%) | 24,641 (19%) | 26,006 (20%) | 26,883 (20%) |
| Metropolitan excluding Seoul | 6,798 (27%) | 8,879 (26%) | 12,234 (26%) | 15,637 (27%) | 18,188 (26%) | 21,310 (26%) | 23,536 (27%) | 26,414 (26%) | 29,867 (27%) | 30,989 (27%) | 32,553 (27%) | 33,988 (27%) | 36,092 (27%) | 37,480 (27%) |
| City | 5,382 (22%) | 7,425 (22%) | 10.296 (22%) | 12,788 (22%) | 14,822 (21%) | 17,710 (22%) | 18,834 (21%) | 21,177 (21%) | 23,801 (21%) | 25,119 (22%) | 26.662 (22%) | 27,978 (22%) | 29,280 (22%) | 29,902 (22%) |
| Rural | 7,064 (28%) | 9,811 (29%) | 13,589 (29%) | 17,284 (30%) | 21,448 (31%) | 25,342 (31%) | 28,175 (32%) | 31,980 (32%) | 35,505 (32%) | 37,215 (32%) | 39,237 (32%) | 40,040 (32%) | 41,188 (31%) | 42,785 (31%) |
| Types | ||||||||||||||
| Self-employed | 10,940 (44%) | 14,746 (44%) | 19,463 (42%) | 23,176 (40%) | 24,883 (36%) | 28,005 (35%) | 29,326 (33%) | 32,066 (32%) | 35,388 (32%) | 35,267 (30%) | 35,567 (29%) | 35,335 (28%) | 35,780 (27%) | 36,224 (26%) |
| The employee | 13,823 (56%) | 18,844 (56%) | 26,885 (58%) | 34,431 (59%) | 40,354 (58%) | 48,452 (60%) | 54,183 (61%) | 61,945 (62%) | 70,712 (63%) | 75,273 (65%) | 80,720 (66%) | 85,361 (67%) | 90,819 (69%) | 94,609 (69%) |
| Medical aid | 42 (0%) | 36 (0%) | 92 (0%) | 680 (1%) | 3,754 (5%) | 4,521 (6%) | 5,074 (6%) | 5,698 (6%) | 5,744 (5%) | 5,980 (5%) | 6,008 (5%) | 5,951 (5%) | 5,967 (5%) | 6,217 (5%) |
| Income level | ||||||||||||||
| The first | 3,015 (12%) | 4,678 (14%) | 6,224 (14%) | 8,766 (15%) | 9,697 (15%) | 10,890 (14%) | 11,324 (14%) | 13,153 (14%) | 14,702 (14%) | 15,966 (15%) | 16,723 (14%) | 18,373 (15%) | 19,000 (15%) | 20,671 (16%) |
| The second | 3,471 (14%) | 4,468 (13%) | 6,831 (15%) | 7,029 (12%) | 9,532 (15%) | 10,285 (14%) | 11,944 (14%) | 13,404 (14%) | 15,608 (15%) | 15,510 (14%) | 17,382 (15%) | 16.910 (14%) | 18,228 (15%) | 18,228 (14%) |
| The third | 5,140 (21%) | 5,945 (18%) | 8,044 (18%) | 10,559 (19%) | 10,383 (16%) | 13,397 (18%) | 14,198 (17%) | 16,374 (18%) | 17,945 (17%) | 18,992 (17%) | 19,278 (17%) | 20,133 (17%) | 21,325 (17%) | 21,757 (17%) |
| The fourth | 5,559 (23%) | 8,195 (25%) | 10,736 (23%) | 12,504 (22%) | 14,968 (23%) | 17,403 (23%) | 18,950 (23%) | 20,970 (23%) | 24,012 (23%) | 24,734 (23%) | 25,823 (22%) | 26,825 (22%) | 27,739 (22%) | 28,792 (22%) |
| The fifth | 7,306 (30%) | 9,970 (30%) | 14,036 (31%) | 18,149 (32%) | 19,972 (31%) | 23,748 (31%) | 26,329 (32%) | 29,272 (31%) | 32,952 (31%) | 34,411 (31%) | 36,138 (31%) | 37,498 (31%) | 39,349 (31%) | 40,377 (31%) |
Results were rounded.